Phaseline

Companies › 3H Pharmaceuticals

3H Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
3H-10000–Phase 1Lung CancerJan 2028
3HP-2827
FGFR2 inhibitor
FGFR2Phase 1Solid Tumors With FGFR2 Alterations, AdultJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT073547113H-10000Phase 1Lung CancerOncologyJan 2028
NCT063785933HP-2827Phase 1Solid Tumors With FGFR2 Alterations, AdultOncologyJun 2028

Targets

FGFR2 (1)

Companies with the same targets

Tyra Biosciences KinoTeck Therapeutics AstraZeneca Johnson & Johnson (Janssen) Hangzhou Zhongmei Huadong Pharmaceutical Taiho Oncology Elevar Therapeutics BeOne Medicines Exelixis QED Therapeutics, a BridgeBio company

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.